Vaccitech plc (VACC) IPO Opens 20% Lower

Today's IPO for Vaccitech plc (NASDAQ: VACC) opened for trading at $13.62 after pricing 6,500,000 American Depositary Shares representing 6,500,000 ordinary shares at an initial public offering price of $17.00 per ADS.

Morgan Stanley, Jefferies, Barclays and William Blair are acting as book-runners for the offering. H.C. Wainwright & Co. is acting as lead manager for the offering.

Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The company’s proprietary platform comprises proprietary modified simian adenoviral vectors, known as ChAdOx1 and ChAdOx2, as well as the well-validated Modified Vaccinia Ankara, or MVA, boost vector, both with demonstrable safety profiles and without the ability to replicate in humans. The combination of a ChAdOx prime treatment with subsequent MVA boost has consistently generated significantly higher magnitudes of CD8+ T cells compared with other technologies and approaches. The company has a broad pipeline of both clinical and preclinical stage therapeutic programs in solid tumors and viral infections and prophylactic viral vaccine programs. Vaccitech co-invented a COVID-19 vaccine with the University of Oxford, now approved for use in many territories and exclusively licensed worldwide to AstraZeneca through Oxford University Innovation, or OUI. Vaccitech is entitled to receive a share of the milestones and royalty income received by OUI from AstraZeneca.

You May Also Be Interested In